載入中
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
前收盤價
US$112.08
−US$0.32 · -0.28%
盤後
US$112.08
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
日內區間
目前US$112.08
52週區間
目前US$112.08
盤中時間採用ET。市場資料可能有所延遲。
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
日內區間
目前US$112.08
52週區間
目前US$112.08
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3920萬 USD | 4707.2萬 USD | 7859.2萬 USD | 4682.6萬 USD | 7283.2萬 USD |
| 毛利 | 3920萬 USD | 4707.2萬 USD | 7859.2萬 USD | 4682.6萬 USD | 7283.2萬 USD |
| 研究與開發 | 3.17億 USD | 2.4億 USD | 1.89億 USD | 1.64億 USD | 1.37億 USD |
| 銷售、一般及管理費用 | 6820萬 USD | 6353.4萬 USD | 5504.1萬 USD | 4383.4萬 USD | 3634.5萬 USD |
| 營業費用 | 3.89億 USD | 3.09億 USD | 2.44億 USD | 2.08億 USD | 1.73億 USD |
| 利息收入 | 3802.6萬 USD | 3802.6萬 USD | 1876.4萬 USD | 662.4萬 USD | 48.8萬 USD |
| 利息支出 | 24.9萬 USD | 24.9萬 USD | 19.6萬 USD | 17.6萬 USD | 17.5萬 USD |
| 折舊和攤銷 | 831.3萬 USD | 737.3萬 USD | 356.5萬 USD | 297.7萬 USD | 239.7萬 USD |
| 營業利益 | −3.49億 USD | −2.62億 USD | −1.66億 USD | −1.61億 USD | −1.01億 USD |
| 淨利 | −3.11億 USD | −2.24億 USD | −1.47億 USD | −1.55億 USD | −1億 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2.49億0.01%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1.84億0.24%787.4億 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap ETFVB1.8億0.10%1853億 USD0.03%US$288.16-0.46%
State Street SPDR S&P Biotech ETFXBI1.18億1.20%103.03億 USD0.35%US$151.4-1.54%
Vanguard Morningstar Small-Cap Growth ETFVBK1.03億0.23%447億 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF8745.7萬0.09%954億 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB6516.41萬0.60%108.2億 USD0.44%US$204.26-1.08%
iShares Russell 2000 Growth ETFIWO5372.6萬0.39%139.17億 USD0.24%US$353.71-0.86%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
